The aim of the present study was to present results after six months following the treatment of intrabony defects with Emdogain-TS®. Twenty-six intrabony defects were treated with enamel matrix proteins (EMD) and PerioGlas® (Emdogain-TS®, Institut Straumann AG, Waldenburg, Switzerland) (EMD-TS®). The following clinical parameters were evaluated at Baseline and at six months after treatment: plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), gingival recession (GR) and clinical attachment level (CAL). The primary outcome variable was CAL. The sites treated with EMD-TS® demonstrated mean CAL changes from 9.0 ± 2.0 mm to 5.9 ± 1.4 mm (p<0.001) at six months. At six months, the mean PD was reduced from 7.5 ± 1.6 mm to 3.7 ± 1.0 mm (p<0.001), and the mean GR increased from 1.5 ± 1.2 mm to 2.2 ± 0.9 mm (p < 0.001). It can be concluded that the treatment of intrabony defects with EMD- TS® results in significant improvements of the investigated clinical parameters.
Keywords: regenerative periodontal therapy, enamel matrix proteins, intrabony periodontal defects, PerioGlas®, Emdogain-TS®